Regarding AD diagnosis tools, recent works focused on the evaluation of plasma biomarkers (total-Tau (t-Tau), phosphorylated Tau (p-Tau181, p-Tau217), neurofilament light (NfL), GFAP, Aβ42, Aβ40) [9,10]. This evidence concerns the gene MAPT and Alzheimer disease.